Anti-inflammatory agents other than corticosteroid in SARs-CoV-2 pneumonia
Clinical Critical Care · 2021
DOI: 10.54205/ccc.v29i.252686 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Critical Care, 2021. Verfasst von Pongdhep Theerawit. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The SARs-CoV-2 results in hyperinflammation among infected patients. This condition leads to serious organ injury, especially in the lungs. Therefore, the main treatment option, in addition to anti-viral agents, is the administration of corticosteroids. However, in many cases, inadequate response to corticosteroids has been observed—other anti-inflammatory agents, such as interleukin-6 inhibitor, kinase inhibitor, etc., play an essential role in reducing this severe complication.
Zitieren
APA
Theerawit, P. (2021). Anti-inflammatory agents other than corticosteroid in SARs-CoV-2 pneumonia. Clinical Critical Care. https://doi.org/10.54205/ccc.v29i.252686
Vancouver
Theerawit P. Anti-inflammatory agents other than corticosteroid in SARs-CoV-2 pneumonia. Clinical Critical Care. 2021. doi:10.54205/ccc.v29i.252686
BibTeX
@article{Theerawit2021,
author = {Theerawit, Pongdhep},
title = {Anti-inflammatory agents other than corticosteroid in SARs-CoV-2 pneumonia},
journal = {Clinical Critical Care},
year = {2021},
doi = {10.54205/ccc.v29i.252686}
}
EUVIMED